Current management of lupus nephritis

Best Practice and Research: Clinical Rheumatology

Volumn 27, Issue 3, 2013, Pages 319-328

  Houssiau, Frédéric A ^a   Lauwerys, Bernard R ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Immunosuppression; Lupus nephritis; Optimal care; Treatment

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADULT; ARTICLE; CASE REPORT; FEMALE; HISTOPATHOLOGY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

IMMUNOSUPPRESSION; LUPUS NEPHRITIS; OPTIMAL CARE; TREATMENT;

ADULT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; PROGNOSIS; PULSE THERAPY, DRUG; QUALITY OF LIFE;

EID: 85027935112     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2013.07.004     Document Type: Review

References (40)

1. R. Cervera, M.A. Khamashta, J. Font, G.D. Sebastiani, A. Gil, and P. Lavilla Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients Medicine (Baltimore) 82 2003 299 308
2. K.H. Costenbader, A. Desai, G.S. Alarcon, L.T. Hiraki, T. Shaykevich, and M.A. Brookhart Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006 Arthritis & Rheumatism 63 2011 1681 1688
3. C.C. Mok Prognostic factors in lupus nephritis Lupus 14 2005 39 44
4. F.A. Houssiau, C. Vasconcelos, D. D'Cruz, G.D. Sebastiani, E. de Ramon Garrido, and M.G. Danieli Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial Arthritis & Rheumatism 50 2004 3934 3940
5. S.M. Korbet, E.J. Lewis Collaborative Study Group Severe lupus nephritis: the predictive value of a >=50 % reduction in proteinuria at 6 months Nephrology Dialysis Transplantation Jun 19 2013 10.1093/ndt/gft201 [Epub ahead of print]
6. N. Costedoat-Chalumeau, Z. Amoura, J.S. Hulot, G. Aymard, G. Leroux, and D. Marra Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus Annals of the Rheumatic Diseases 66 2007 821 824
7. J.J. Weening, V.D. D'Agati, M.M. Schwartz, S.V. Seshan, C.E. Alpers, and G.B. Appel The classification of glomerulonephritis in systemic lupus erythematosus revisited Journal of the American Society of Nephrology 15 2004 241 250
8. M.G. Tektonidou, F. Sotsiou, and L. Nakopoulou Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome Arthritis & Rheumatism 50 2004 2569 2579
9. C.M. Haring, A. Rietveld, J.A. van den Brand, and J.H. Berden Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes Journal of the American Society of Nephrology 23 2012 149 154
10. M. El Hachmi, M. Jadoul, C. Lefèbvre, G. Depresseux, and Houssiau FA Relapses of lupus nephritis: incidence, risk factors serology and impact on outcome Lupus 12 2003 692 696
11. D. Wofsy, J.L. Hillson, and B. Diamond Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials Arthritis & Rheumatism 65 2013 1586 1591
12. R. Furie, K. Nicholls, T.T. Cheng, F. Houssiau, R. Burgos-Vargas, and S.L. Chen Efficacy and safety of abatacept in lupus nephritis Annals of the Rheumatic Diseases 71 Suppl. 3 2012 534
13. G.K. Bertsias, M. Tektonidou, Z. Amoura, M. Aringer, I. Bajema, and J.H.M. Berden Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis Annals of the Rheumatic Diseases 71 2012 1771 1782
14. B.H. Hahn, M.A. McMahon, A. Wikinson, W.D. Wallace, D.I. Daikh, and J.D. Fitzgerald American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis Arthritis Care & Research (Hoboken) 64 2012 797 808
15. D. Gladman, E. Ginzler, C. Goldsmith, P. Fortin, M. Liang, and M. Urowitz The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus Arthritis & Rheumatism 39 1996 363 369
16. S.A. Chambers, E. Allen, A. Rahman, and D. Isenberg Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years Rheumatology (Oxford) 48 2009 673 675
17. M. Thamer, M.A. Hernan, Y. Zhang, D. Cotter, and M. Petri Prednisone, lupus activity, and permanent organ damage Journal of Rheumatology 36 2009 560 564
18. R. Fischer-Betz, G. Chehab, O. Sander, S. Vordenbaümen, A. Voiculescu, and R. Brinks Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study Journal of Rheumatology 39 2012 2111 2117
19. M.B. Condon, D. Ashby, R.J. Pepper, H.T. Cook, J.B. Levy, and M. Griffith Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids Annals of the Rheumatic Diseases 72 2013 1280 1286
20. F.A. Houssiau, and D. Isenberg Towards treating lupus nephritis without oral steroids: a dream-come-true? Annals of the Rheumatic Diseases 72 2013 1271 1272
21. H.A. Austin 3rd, J.H. Klippel, J.E. Balow, N.G. le Riche, A.D. Steinberg, and P.H. Plotz Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs New England Journal of Medicine 314 1986 614 619
22. D.T. Boumpas, H.A. Austin 3rd, E.M. Vaughn, J.H. Klippel, A.D. Steinberg, and C.H. Yarboro Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis Lancet 340 1992 741 745
23. M.F. Gourlev, H.A. Austin 3rd, D. Scott, C.H. Yarboro, E.M. Vaughan, and J. Muir Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial Annals of Internal Medicine 125 1996 549 557
24. F.A. Houssiau, C. Vasconcelos, D. D'Cruz, G.D. Sebastiani, E. de Ramon Garrido, and M.G. Danieli Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide Arthritis & Rheumatism 46 2002 2121 2131
25. F.A. Houssiau, C. Vasconcelos, D. D'Cruz, G.D. Sebastiani, E. de Ramon Garrido, and M.G. Danieli The 10-year follow-up of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide Annals of the Rheumatic Diseases 69 2010 61 64
26. T.M. Chan, F.K. Li, C.S. Tang, R.W. Wong, G.X. Fang, and Y.L. Ji Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group New England Journal of Medicine 343 2000 1156 1162
27. E.M. Ginzler, M.A. Dooley, C. Aranow, M.Y. Kim, J. Buyon, and J.T. Merrill Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis New England Journal of Medicine 353 2005 2219 2228
28. L.M. Ong, L.S. Hooi, T.O. Lim, B.L. Goh, G. Ahmad, and R. Ghazalli Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis Nephrology (Carlton) 10 2005 504 510
29. G.B. Appel, G. Contreras, M.A. Dooley, E.M. Ginzler, D. Isenberg, and D. Jayne Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis Journal of the American Society of Nephrology 20 2009 1103 1112
30. Z. Tang, G. Yang, C. Yu, Y. Yu, J. Wang, and W. Hu Effects of mycophenolate mofetil for patients with crescentic lupus nephritis Nephrology (Carlton) 13 2008 702 707
31. B.H. Rovin, S.V. Parikh, L.A. Hebert, T.M. Chan, C.C. Mok, and E.M. Ginzler Lupus nephritis: induction therapy in severe lupus nephritis - should MMF be considered the drug of choice? Clinical Journal of the American Society of Nephrology 8 2013 147 153
32. J. Hogan, M.H. Schwenk, and J. Radhakrishnan Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? Kidney International 82 2012 1256 1260
33. H.S. Koo, Y.C. Kim, S.W. Lee, D.K. Kim, K.H. Oh, and K.W. Joo The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis Lupus 20 2011 1442 1449
34. M.A. Dooley, D. Jayne, E.M. Ginzler, D. Isenberg, N.J. Olsen, and D. Wofsy Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis New England Journal of Medicine 365 2011 1886 1895
35. F.A. Houssiau, D. D'Cruz, S. Sangle, P. Remy, C. Vasconcelos, and R. Petrovic Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial Annals of the Rheumatic Diseases 69 2010 2083 2089
36. G. Moroni, B. Gallelli, S. Quaglini, G. Banfi, E. Rivolta, and P. Messa Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up Nephrology Dialysis Transplantation 21 2006 1541 1548
37. J.T. Merrill, C.M. Neuwelt, D.J. Wallace, J.C. Shanahan, K.M. Latinis, and J.C. Oates Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial Arthritis & Rheumatism 62 2010 222 233
38. B.H. Rovin, R. Furie, K. Latinis, R.J. Looney, F.C. Fervenza, and J. Sanchez-Guerrero Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study Arthritis & Rheumatism 64 2012 1215 1226
39. E.F. Mysler, A.J. Spindler, R. Guzman, M. Bijl, D. Jayne, and R.A. Furie Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from the randomized, double-blind phase III BELONG Study Arthritis & Rheumatism Jun 5 2013 10.1002/art.38037 [Epub ahead of print]
40. J.T. Merrill, R. Burgos-Vargas, R. Westhovens, A. Chalmers, D. D'Cruz, and D.J. Wallace The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial Arthritis & Rheumatism 62 2010 3077 3087